ethyl 7-acetoxy-1-benzothiophene-5-carboxylate | 955886-80-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: ethyl 7-acetoxy-1-benzothiophene-5-carboxylate
• 英文别名: Ethyl 7-(acetyloxy)benzo[b]thiophene-5-carboxylate；ethyl 7-acetyloxy-1-benzothiophene-5-carboxylate
• CAS: 955886-80-3
• 化学式: C₁₃H₁₂O₄S
• 分子量: 264.302
• InChiKey: ZYFLMFLBMLCQAF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  80.8
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS
  申请人：Bai Hao

  公开号：US20080280875A1

  公开（公告）日：2008-11-13

  The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein: Ring A is (4-12)-membered heterocyclyl; Ring B is a fused benzene ring selected from the group consisting of: Ring A, ring B, ring C, R 1 , R 1a , R 2 , R 3 , R 4 , L 2 , n, t, w, and z are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of glucokinase, the method comprising administering to a mammal an effective amount of a compound of formula (I).

  本发明涉及以下式(I)的化合物：或其药用可接受的盐或溶剂，其中：环A为(4-12)成员杂环基；环B是从以下组中选择的融合苯环之一：环A、环B、环C、R1、R1a、R2、R3、R4、L2、n、t、w和z如规范中所定义。本发明还涉及包括式(I)的化合物的药物组合物以及治疗通过调节葡萄糖激酶介导的疾病的方法，该方法包括向哺乳动物施用有效量的式(I)的化合物。
• MORPHOLINE DERIVATIVE
  申请人：Akatsuka Hidenori

  公开号：US20100240644A1

  公开（公告）日：2010-09-23

  The present invention provides a morpholine derivative of the formula [I]; wherein R 1 is a substituted alkyl group, an optionally substituted aryl group, an optionally substituted heterocyclo group, a cycloalkyl group or an alkyl group; R 2 is a substituted alkyl group, an optionally substituted aryl group, an optionally substituted heterocyclo group, an optionally substituted alkylcarbonyl group, an optionally substituted arylcarbonyl group, an optionally substituted heterocyclo-substituted carbonyl group or a cycloalkylcarbonyl group; T is a methylene group or a carbonyl group; R 3 , R 4 , R 5 and R 6 are the same or different and a hydrogen atom, an optionally substituted carbamoyl group or an optionally substituted alkyl group; or pharmaceutically acceptable salts thereof. These compounds are useful as a renin inhibitor.

  本发明提供了公式[I]的吗啡啶衍生物；其中R1是取代的烷基，可选取代的芳基，可选取代的杂环基，环烷基或烷基；R2是取代的烷基，可选取代的芳基，可选取代的杂环基，可选取代的烷基羰基，可选取代的芳基羰基，可选取代的杂环取代羰基或环烷基羰基；T是亚甲基或羰基；R3，R4，R5和R6相同或不同，是氢原子，可选取代的氨基甲酰基或可选取代的烷基；或其药学上可接受的盐。这些化合物可用作肾素抑制剂。
• Fused Phenyl Amido Heterocyclic Compounds
  申请人：Bai Hao

  公开号：US20110039821A1

  公开（公告）日：2011-02-17

  The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein: Ring A is (4-12)-membered heterocyclyl; Ring B is a fused benzene ring selected from the group consisting of: Ring A, ring B, ring C, R 1 , R 1a , R 2 , R 3 , R 4 , L 2 , n, t, w, and z are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of glucokinase, the method comprising administering to a mammal an effective amount of a compound of formula (I).

  本发明涉及以下式子的化合物(I)或其药学上可接受的盐或溶剂： 其中，环A是(4-12)成员杂环基；环B是从以下组中选择的融合苯环：环A、环B、环C、R1、R1a、R2、R3、R4、L2、n、t、w和z在规范中定义。本发明还涉及包括式(I)化合物的药物组合物和通过调节葡萄糖激酶介导的疾病的治疗方法，该方法包括向哺乳动物施用式(I)化合物的有效量。
• Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases
  申请人：Pfizer Products Inc.

  公开号：EP2463283A1

  公开（公告）日：2012-06-13

  The present invention relates to a compound of formula (VIa): or a pharmaceutically acceptable s alt or solvate thereof, wherein Ring A is pyrazinyl and L1, R1, R1a, R4, L2, R2, R3, w and n are as defined herein. Such compounds are glucokinase agonists and useful in the treatment of diseases including diabetes and obesity.

  本发明涉及一种式 (VIa) 的化合物： 或其药学上可接受的 s alt 或溶液，其中环 A 是吡嗪基，L1、R1、R1a、R4、L2、R2、R3、w 和 n 如本文所定义。此类化合物是葡萄糖激酶激动剂，可用于治疗糖尿病和肥胖症等疾病。
• MORPHOLINE DERIVATIVES AS RENIN INHIBITORS
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP2168952B1

  公开（公告）日：2017-02-15